VANCOUVER, BC – December 20, 2022 – Izotropic Corporation (“Izotropic” or the “Company”) (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company commercializing IzoView, a dedicated breast CT (computed tomography) imaging platform, for the more accurate detection and diagnosis of breast cancers, announces the results of its Annual General Meeting held on December 19, 2022.
Company matters submitted to shareholders for approval as set out in the Company's Notice of Meeting and Management Information Circular, dated November 17, 2022, were approved by the requisite majority of votes cast at the meeting.
The primary matters acted upon were:
- Approval of all nominees to sit as directors of the corporation for the ensuing year and the number of directors to be set at six;
- Approval of the appointment of auditor Dale Matheson Carr-Hilton LaBonte LLP.
Clarifying Amended and Restated Financial Statements
A news release was disseminated on December 16, 2022, announcing the amendment and restatement of the Company's Financial Statements for the three months that ended July 31, 2022. Izotropic confirms that no changes were made to the financial information in the statements and that the restatement was not associated with an error or a correction of any kind. The Company’s auditor has reviewed the statements as a requirement for additional filings related to future financing and uplisting plans, and the amendment and restatement was required to note the auditor’s review.
ON BEHALF OF THE BOARD
Investor Relations Contact:
Toll Free: 1-833-IZOCORP ext.1
Media Inquiries Contact:
Toll Free: 1-833-IZOCORP ext.3
About Izotropic Corporation
Izotropic Corporation is the only publicly traded company commercializing a dedicated breast CT imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers. To expedite patient and provider access to IzoView, Izotropic's initial clinical study intends to demonstrate superior performance of diagnostic breast CT imaging over diagnostic mammography procedures. In follow-on clinical studies, Izotropic intends to validate platform applications, including breast screening in radiology, treatment planning and monitoring in surgical oncology, and breast reconstruction and implant monitoring in plastic and reconstructive surgery.
This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.
These statements are not guarantees of performance and involve risks including those related to capital requirements, and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView is not yet approved for sale.